SYSTEMATIC REVIEW article
Front. Pharmacol.
Sec. Drugs Outcomes Research and Policies
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1556705
This article is part of the Research TopicIncreasing Importance of Patients-generated Real World Data for Healthcare Policy Decisions about Medicinal Products: Volume IIIView all articles
Efficacy and safety of oral minoxidil in the treatment of alopecia: a single-arm rate meta-analysis and systematic review
Provisionally accepted
- Department of Burns and Plastic Surgery, Yantaishan Hospital, Yantai, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Hair loss is a prevalent aesthetic concern that impacts the quality of life and self-image of numerous individuals. While topical minoxidil has been extensively utilized in addressing hair loss for several decades, the effectiveness and safety of oral minoxidil are still a topic of debate. Despite its use in certain clinical settings, the precise efficacy and safety of oral minoxidil have not been conclusively validated. Hence, conducting a one-arm rate meta-analysis and systematic review to assess the efficacy and safety of oral minoxidil in treating alopecia holds significant importance. This endeavor aims to furnish additional evidence to support clinical practice and offer guidance for future research in this domain.Methods: We conducted a comprehensive search on electronic databases including PubMed, Embase, Cochrane Library, and Web of Science from their inception up to October 1, 2024. The primary objective was to assess both the efficacy (measured by the degree of symptom improvement) and safety (including adverse event incidence) of oral minoxidil in the treatment of hair loss.Results: A total of 2,933 patients from 27 studies were included in the analysis. The efficacy of oral minoxidil for treating alopecia was primarily assessed based on the degree of symptom improvement. Among the participants, 35% (95% CI: 22%-49%) experienced significant symptom improvement, 47% (95% CI: 38%-55%) showed symptom improvement, and 26% (95% CI: 16%-37%) had stable symptoms. The incidence of adverse events in the safety evaluation was reported at 27% (95% CI: 18%-36%).Conclusion: This systematic review and meta-analysis indicate that individuals with hair loss may derive benefits from oral minoxidil, particularly at doses exceeding 1mg. Nonetheless, additional research or data is essential to definitively establish its efficacy and safety.
Keywords: Minoxidil, Alopecia, efficacy, Safety, Meta-analysis
Received: 07 Jan 2025; Accepted: 19 May 2025.
Copyright: © 2025 Liu, Liu, Shi, Wang, Sui, Zhang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Bowen Wang, Department of Burns and Plastic Surgery, Yantaishan Hospital, Yantai, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.